Webcast – CHMP rekommenderar att Oncopeptides Pepaxti får ett fullt godkännande i EU

June 23, 2022

On June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.

Conference call for investors, analysts, and media
Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022. The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor.

The webcast was recorded and can be seen via https://tv.streamfabriken.com/2022-pressconference.

Link to the press release


Presentation in PDF